drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01612 | DB14881 | 1,637 | 180 | [
"DDInter92",
"DDInter1329"
] | Amyl Nitrite | Oliceridine | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1637,
24,
180
]
],
[
[
1637,
63,
401
],
[
401,
24,
180
]
],
[
[
1637,
24,
407
],
[
407,
24,
180
]
],
[
[
1637,
63,
593
],
[
593,
... | [
[
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Amyl Nitrite",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Opium and Op... |
DB00352 | DB00598 | 482 | 1,523 | [
"DDInter1814",
"DDInter1013"
] | Tioguanine | Labetalol | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Moderate | 1 | [
[
[
482,
24,
1523
]
],
[
[
482,
24,
935
],
[
935,
1,
1523
]
],
[
[
482,
24,
1274
],
[
1274,
63,
1523
]
],
[
[
482,
21,
28658
],
[
28658,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Labetalol (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that co... |
DB00476 | DB05812 | 109 | 1,374 | [
"DDInter608",
"DDInter8"
] | Duloxetine | Abiraterone | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
109,
24,
1374
]
],
[
[
109,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
109,
21,
28661
],
[
28661,
60,
1374
]
],
[
[
109,
24,
760
],
[
760,... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)"... | Duloxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Duloxetine (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Abiraterone (Compound)
Duloxetine may cause a moderate interaction that could exacerbate diseases when ... |
DB00446 | DB06590 | 597 | 1,682 | [
"DDInter351",
"DDInter329"
] | Chloramphenicol | Ceftaroline fosamil | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections. Community-acquired bacterial pneumonia. | Moderate | 1 | [
[
[
597,
24,
1682
]
],
[
[
597,
24,
1462
],
[
1462,
1,
1682
]
],
[
[
597,
63,
149
],
[
149,
40,
1682
]
],
[
[
597,
24,
1024
],
[
1024,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftaroline fosamil"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditor... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren and Cefditoren (Compound) resembles Ceftaroline fosamil (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles C... |
DB06616 | DB08827 | 594 | 990 | [
"DDInter224",
"DDInter1085"
] | Bosutinib | Lomitapide | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
594,
25,
990
]
],
[
[
594,
64,
1080
],
[
1080,
1,
990
]
],
[
[
594,
6,
8374
],
[
8374,
45,
990
]
],
[
[
594,
54,
19133
],
[
19133,
... | [
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} (Co... | Bosutinib may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Bosutinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Bosutinib (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)... |
DB00384 | DB06754 | 1,275 | 707 | [
"DDInter1859",
"DDInter471"
] | Triamterene | Danaparoid | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Moderate | 1 | [
[
[
1275,
24,
707
]
],
[
[
1275,
24,
222
],
[
222,
24,
707
]
],
[
[
1275,
24,
365
],
[
365,
64,
707
]
],
[
[
1275,
24,
848
],
[
848,
... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin and Da... |
DB01229 | DB12141 | 973 | 971 | [
"DDInter1377",
"DDInter817"
] | Paclitaxel | Gilteritinib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
973,
24,
971
]
],
[
[
973,
63,
112
],
[
112,
23,
971
]
],
[
[
973,
24,
1097
],
[
1097,
24,
971
]
],
[
[
973,
63,
1335
],
[
1335,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and ... |
DB01017 | DB08880 | 1,669 | 1,510 | [
"DDInter1224",
"DDInter1771"
] | Minocycline | Teriflunomide | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1669,
25,
1510
]
],
[
[
1669,
24,
1193
],
[
1193,
62,
1510
]
],
[
[
1669,
24,
242
],
[
242,
63,
1510
]
],
[
[
1669,
63,
1031
],
[
1031... | [
[
[
"Minocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Z... | Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir... |
DB11730 | DB11978 | 351 | 124 | [
"DDInter1588",
"DDInter822"
] | Ribociclib | Glasdegib | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Major | 2 | [
[
[
351,
25,
124
]
],
[
[
351,
64,
1135
],
[
1135,
23,
124
]
],
[
[
351,
62,
1247
],
[
1247,
23,
124
]
],
[
[
351,
23,
466
],
[
466,
... | [
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may ... | Ribociclib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may c... |
DB00835 | DB01219 | 100 | 716 | [
"DDInter245",
"DDInter473"
] | Brompheniramine | Dantrolene | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
100,
24,
716
]
],
[
[
100,
6,
8374
],
[
8374,
45,
716
]
],
[
[
100,
24,
1609
],
[
1609,
63,
716
]
],
[
[
100,
63,
13
],
[
13,
24... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (C... | Brompheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dantrolene (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Br... |
DB00938 | DB06589 | 455 | 1,250 | [
"DDInter1635",
"DDInter1400"
] | Salmeterol | Pazopanib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
455,
24,
1250
]
],
[
[
455,
6,
3486
],
[
3486,
45,
1250
]
],
[
[
455,
21,
29264
],
[
29264,
60,
1250
]
],
[
[
455,
63,
307
],
[
307,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Salmeterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Salmeterol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Pazopanib (Compound)
Salmeterol (Compound) causes Rhinorrhoea (Side Effect) and Rhinorrhoea (Side Effect) is caused by Pazopanib (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Mod... |
DB00656 | DB09330 | 827 | 985 | [
"DDInter1851",
"DDInter1352"
] | Trazodone | Osimertinib | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
827,
25,
985
]
],
[
[
827,
23,
112
],
[
112,
23,
985
]
],
[
[
827,
24,
480
],
[
480,
24,
985
]
],
[
[
827,
24,
657
],
[
657,
63,... | [
[
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Trazodone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formo... |
DB06209 | DB15035 | 256 | 503 | [
"DDInter1508",
"DDInter1959"
] | Prasugrel | Zanubrutinib | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
256,
25,
503
]
],
[
[
256,
63,
222
],
[
222,
24,
503
]
],
[
[
256,
24,
738
],
[
738,
24,
503
]
],
[
[
256,
62,
752
],
[
752,
24,... | [
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Nirap... |
DB00686 | DB01088 | 383 | 714 | [
"DDInter1424",
"DDInter908"
] | Pentosan polysulfate | Iloprost | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
383,
24,
714
]
],
[
[
383,
24,
1479
],
[
1479,
24,
714
]
],
[
[
383,
63,
1432
],
[
1432,
24,
714
]
],
[
[
383,
24,
1564
],
[
1564,
... | [
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsal... | Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases... |
DB00656 | DB01001 | 827 | 688 | [
"DDInter1851",
"DDInter1632"
] | Trazodone | Salbutamol | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
827,
24,
688
]
],
[
[
827,
24,
455
],
[
455,
24,
688
]
],
[
[
827,
24,
1148
],
[
1148,
63,
688
]
],
[
[
827,
6,
8374
],
[
8374,
... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isopre... |
DB00344 | DB00757 | 1,302 | 1,166 | [
"DDInter1543",
"DDInter581"
] | Protriptyline | Dolasetron | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
1302,
25,
1166
]
],
[
[
1302,
24,
19
],
[
19,
40,
1166
]
],
[
[
1302,
24,
85
],
[
85,
1,
1166
]
],
[
[
1302,
6,
12523
],
[
12523,
... | [
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyo... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Dolasetron (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Dolasetron (Compou... |
DB00622 | DB00712 | 1,081 | 1,274 | [
"DDInter1287",
"DDInter763"
] | Nicardipine | Flurbiprofen | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
1081,
24,
1274
]
],
[
[
1081,
6,
6017
],
[
6017,
45,
1274
]
],
[
[
1081,
7,
7088
],
[
7088,
46,
1274
]
],
[
[
1081,
21,
28769
],
[
287... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Nicardipine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compoun... | Nicardipine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Flurbiprofen (Compound)
Nicardipine (Compound) upregulates ME2 (Gene) and ME2 (Gene) is upregulated by Flurbiprofen (Compound)
Nicardipine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofe... |
DB01121 | DB01611 | 94 | 1,487 | [
"DDInter1437",
"DDInter893"
] | Phenacemide | Hydroxychloroquine | Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
94,
24,
1487
]
],
[
[
94,
40,
136
],
[
136,
63,
1487
]
],
[
[
94,
63,
770
],
[
770,
24,
1487
]
],
[
[
94,
40,
1144
],
[
1144,
24... | [
[
[
"Phenacemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Phenacemide",
"{u} (Compound) resembles {v} (Compound)",
"Lacosamide"
],
[
"Lacosamide",
"{u} may cause... | Phenacemide (Compound) resembles Lacosamide (Compound) and Lacosamide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Phenacemide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interactio... |
DB00208 | DB08875 | 1,018 | 1,618 | [
"DDInter1804",
"DDInter262"
] | Ticlopidine | Cabozantinib | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1018,
25,
1618
]
],
[
[
1018,
24,
41
],
[
41,
63,
1618
]
],
[
[
1018,
24,
673
],
[
673,
24,
1618
]
],
[
[
1018,
23,
286
],
[
286,
... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"L... | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Aripipr... |
DB01261 | DB12147 | 170 | 241 | [
"DDInter1679",
"DDInter661"
] | Sitagliptin | Erdafitinib | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Moderate | 1 | [
[
[
170,
24,
241
]
],
[
[
170,
24,
850
],
[
850,
24,
241
]
],
[
[
170,
63,
629
],
[
629,
24,
241
]
],
[
[
170,
63,
1220
],
[
1220,
2... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00757 | DB08868 | 1,166 | 1,011 | [
"DDInter581",
"DDInter737"
] | Dolasetron | Fingolimod | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1166,
25,
1011
]
],
[
[
1166,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
1166,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
1166,
23,
1247
],
[
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Dolasetron",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingoli... | Dolasetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Dolasetron (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethox... |
DB06691 | DB13913 | 849 | 1,536 | [
"DDInter1155",
"DDInter175"
] | Mepyramine | Belladonna | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family _Solanaceae_. Its roots, leaves and fruits contain , , and mostly, . These alkaloids are naturally-occurring muscarinic antagonists. is a non-selective muscarinic antagonist that is mainly used as ... | Moderate | 1 | [
[
[
849,
24,
1536
]
],
[
[
849,
63,
128
],
[
128,
24,
1536
]
],
[
[
849,
24,
412
],
[
412,
24,
1536
]
],
[
[
849,
74,
100
],
[
100,
... | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
... | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Eluxa... |
DB01095 | DB09280 | 671 | 1,604 | [
"DDInter769",
"DDInter1101"
] | Fluvastatin | Lumacaftor | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
671,
24,
1604
]
],
[
[
671,
63,
522
],
[
522,
24,
1604
]
],
[
[
671,
24,
1468
],
[
1468,
24,
1604
]
],
[
[
671,
24,
1501
],
[
1501,
... | [
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[... | Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Pon... |
DB11601 | DB11760 | 1,270 | 119 | [
"DDInter1889",
"DDInter1742"
] | Tuberculin purified protein derivative | Talazoparib | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1270,
24,
119
]
],
[
[
1270,
63,
66
],
[
66,
24,
119
]
],
[
[
1270,
24,
351
],
[
351,
24,
119
]
],
[
[
1270,
24,
1619
],
[
1619,
... | [
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases... | Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Tuberculin purified protein derivative may cause a moderate interaction that could ... |
DB00808 | DB09045 | 1,605 | 52 | [
"DDInter916",
"DDInter607"
] | Indapamide | Dulaglutide | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
1605,
24,
52
]
],
[
[
1605,
24,
170
],
[
170,
23,
52
]
],
[
[
1605,
63,
870
],
[
870,
24,
52
]
],
[
[
1605,
24,
1296
],
[
1296,
... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and ... |
DB06288 | DB12141 | 607 | 971 | [
"DDInter77",
"DDInter817"
] | Amisulpride | Gilteritinib | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
607,
25,
971
]
],
[
[
607,
62,
112
],
[
112,
23,
971
]
],
[
[
607,
64,
485
],
[
485,
24,
971
]
],
[
[
607,
25,
823
],
[
823,
63,... | [
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Amisulpride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Amisulpride may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine ma... |
DB00264 | DB01362 | 88 | 497 | [
"DDInter1200",
"DDInter960"
] | Metoprolol | Iohexol | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Moderate | 1 | [
[
[
88,
24,
497
]
],
[
[
88,
24,
258
],
[
258,
40,
497
]
],
[
[
88,
21,
28681
],
[
28681,
60,
497
]
],
[
[
88,
40,
1121
],
[
1121,
2... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
],
[
... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Metoprolol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Metoprolol (Compound) resembles Bisopr... |
DB00683 | DB06723 | 1,382 | 115 | [
"DDInter1212",
"DDInter58"
] | Midazolam | Aluminum hydroxide | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
1382,
23,
115
]
],
[
[
1382,
21,
28775
],
[
28775,
60,
115
]
],
[
[
1382,
62,
1573
],
[
1573,
23,
115
]
],
[
[
1382,
1,
1565
],
[
1565... | [
[
[
"Midazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Midazolam",
"{u} (Compound) causes {v} (Side Effect)",
"Phlebitis"
],
[
"Phlebitis",
"{u} (Side Effect) is ... | Midazolam (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Aluminum hydroxide (Compound)
Midazolam may cause a minor interaction that can limit clinical effects when taken with Prednisone and Prednisone may cause a minor interaction that can limit clinical effects when taken with Alumi... |
DB00594 | DB11110 | 863 | 603 | [
"DDInter68",
"DDInter1115"
] | Amiloride | Magnesium citrate | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
863,
24,
603
]
],
[
[
863,
24,
870
],
[
870,
24,
603
]
],
[
[
863,
63,
251
],
[
251,
24,
603
]
],
[
[
863,
23,
1545
],
[
1545,
2... | [
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]... | Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Betame... |
DB00631 | DB01118 | 372 | 33 | [
"DDInter405",
"DDInter76"
] | Clofarabine | Amiodarone | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Moderate | 1 | [
[
[
372,
24,
33
]
],
[
[
372,
24,
540
],
[
540,
1,
33
]
],
[
[
372,
7,
7669
],
[
7669,
46,
33
]
],
[
[
372,
18,
13123
],
[
13123,
46... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Clofarabine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Amiodarone (Compound)
Clofarabine (Compound) downregulates ELOVL6 (Gene) a... |
DB00191 | DB00222 | 73 | 245 | [
"DDInter1447",
"DDInter825"
] | Phentermine | Glimepiride | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Moderate | 1 | [
[
[
73,
24,
245
]
],
[
[
73,
24,
959
],
[
959,
1,
245
]
],
[
[
73,
6,
6017
],
[
6017,
45,
245
]
],
[
[
73,
21,
29024
],
[
29024,
60,... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound)
Phentermine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Glimepiride (Compound)
Phentermine (Compound) causes Hypertension (Side Effect) and Hyp... |
DB01394 | DB09098 | 1,554 | 98 | [
"DDInter431",
"DDInter1700"
] | Colchicine | Somatrem | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1554,
24,
98
]
],
[
[
1554,
63,
168
],
[
168,
23,
98
]
],
[
[
1554,
24,
159
],
[
159,
63,
98
]
],
[
[
1554,
64,
609
],
[
609,
24... | [
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotre... |
DB09078 | DB09083 | 1,228 | 880 | [
"DDInter1036",
"DDInter996"
] | Lenvatinib | Ivabradine | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1228,
25,
880
]
],
[
[
1228,
63,
480
],
[
480,
24,
880
]
],
[
[
1228,
24,
659
],
[
659,
24,
880
]
],
[
[
1228,
64,
1011
],
[
1011,
... | [
[
[
"Lenvatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol... | Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilant... |
DB09073 | DB12500 | 951 | 283 | [
"DDInter1379",
"DDInter714"
] | Palbociclib | Fedratinib | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
951,
24,
283
]
],
[
[
951,
62,
271
],
[
271,
23,
283
]
],
[
[
951,
23,
907
],
[
907,
23,
283
]
],
[
[
951,
24,
351
],
[
351,
23,... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Palbociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
... | Palbociclib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine... |
DB00472 | DB08824 | 758 | 591 | [
"DDInter758",
"DDInter959"
] | Fluoxetine | Ioflupane I-123 | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
758,
24,
591
]
],
[
[
758,
21,
29305
],
[
29305,
60,
591
]
],
[
[
758,
1,
109
],
[
109,
24,
591
]
],
[
[
758,
24,
401
],
[
401,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Fluoxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Dysgeusia"
],
[
"Dysgeusia",
"{u} (Side Effect) is... | Fluoxetine (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Ioflupane I-123 (Compound)
Fluoxetine (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Fluoxetine may cause a moderate in... |
DB00047 | DB00679 | 176 | 684 | [
"DDInter932",
"DDInter1796"
] | Insulin glargine | Thioridazine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Moderate | 1 | [
[
[
176,
24,
684
]
],
[
[
176,
24,
146
],
[
146,
40,
684
]
],
[
[
176,
24,
216
],
[
216,
1,
684
]
],
[
[
176,
24,
417
],
[
417,
23,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine (Compound) resembles Thioridazine (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resemb... |
DB00812 | DB01172 | 998 | 416 | [
"DDInter1451",
"DDInter1004"
] | Phenylbutazone | Kanamycin | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
998,
24,
416
]
],
[
[
998,
6,
7720
],
[
7720,
46,
416
]
],
[
[
998,
62,
608
],
[
608,
23,
416
]
],
[
[
998,
24,
712
],
[
712,
63... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (... | Phenylbutazone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound)
Phenylbutazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Kanamycin
Phenylbutazone... |
DB08912 | DB12147 | 1,040 | 241 | [
"DDInter462",
"DDInter661"
] | Dabrafenib | Erdafitinib | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Major | 2 | [
[
[
1040,
25,
241
]
],
[
[
1040,
63,
170
],
[
170,
24,
241
]
],
[
[
1040,
25,
1456
],
[
1456,
24,
241
]
],
[
[
1040,
24,
384
],
[
384,
... | [
[
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitaglip... | Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Dabrafenib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cau... |
DB00220 | DB06203 | 798 | 1,002 | [
"DDInter1276",
"DDInter51"
] | Nelfinavir | Alogliptin | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
798,
24,
1002
]
],
[
[
798,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
798,
6,
12523
],
[
12523,
45,
1002
]
],
[
[
798,
21,
28873
],
[
2887... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
... | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Nelfinavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Alogliptin (Compound)
Nelfinavir (Compound) causes Pancreatitis (Side Effect) and Panc... |
DB01021 | DB01362 | 674 | 497 | [
"DDInter1861",
"DDInter960"
] | Trichlormethiazide | Iohexol | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Moderate | 1 | [
[
[
674,
24,
497
]
],
[
[
674,
18,
7744
],
[
7744,
57,
497
]
],
[
[
674,
1,
323
],
[
323,
24,
497
]
],
[
[
674,
40,
1326
],
[
1326,
... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Trichlormethiazide",
"{u} (Compound) downregulates {v} (Gene)",
"PRR7"
],
[
"PRR7",
"{u} (Gene) is downregu... | Trichlormethiazide (Compound) downregulates PRR7 (Gene) and PRR7 (Gene) is downregulated by Iohexol (Compound)
Trichlormethiazide (Compound) resembles Bendroflumethiazide (Compound) and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
Trichlormethiazide (Compou... |
DB00099 | DB00987 | 440 | 1,224 | [
"DDInter735",
"DDInter460"
] | Filgrastim | Cytarabine | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Moderate | 1 | [
[
[
440,
24,
1224
]
],
[
[
440,
24,
1426
],
[
1426,
1,
1224
]
],
[
[
440,
24,
322
],
[
322,
24,
1224
]
],
[
[
440,
24,
850
],
[
850,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Azacitidine and Azacitidine (Compound) resembles Cytarabine (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that cou... |
DB00224 | DB11979 | 215 | 1,320 | [
"DDInter917",
"DDInter625"
] | Indinavir | Elagolix | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Major | 2 | [
[
[
215,
25,
1320
]
],
[
[
215,
63,
168
],
[
168,
23,
1320
]
],
[
[
215,
24,
608
],
[
608,
23,
1320
]
],
[
[
215,
25,
1297
],
[
1297,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may... |
DB06603 | DB11817 | 39 | 1,259 | [
"DDInter1387",
"DDInter165"
] | Panobinostat | Baricitinib | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
39,
25,
1259
]
],
[
[
39,
76,
1274
],
[
1274,
24,
1259
]
],
[
[
39,
64,
598
],
[
598,
24,
1259
]
],
[
[
39,
24,
949
],
[
949,
24... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening i... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Panobinostat may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Panobinost... |
DB00059 | DB08896 | 1,560 | 292 | [
"DDInter1404",
"DDInter1576"
] | Pegaspargase | Regorafenib | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
1560,
24,
292
]
],
[
[
1560,
24,
79
],
[
79,
1,
292
]
],
[
[
1560,
24,
549
],
[
549,
23,
292
]
],
[
[
1560,
24,
901
],
[
901,
24... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a minor interaction that... |
DB00524 | DB09135 | 811 | 1,211 | [
"DDInter1199",
"DDInter967"
] | Metolazone | Ioxilan | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Moderate | 1 | [
[
[
811,
24,
1211
]
],
[
[
811,
1,
359
],
[
359,
24,
1211
]
],
[
[
811,
63,
1648
],
[
1648,
24,
1211
]
],
[
[
811,
40,
1014
],
[
1014,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may cause a mo... | Metolazone (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction tha... |
DB12267 | DB13928 | 1,476 | 1,385 | [
"DDInter233",
"DDInter1660"
] | Brigatinib | Semaglutide | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1476,
24,
1385
]
],
[
[
1476,
24,
1399
],
[
1399,
63,
1385
]
],
[
[
1476,
63,
839
],
[
839,
24,
1385
]
],
[
[
1476,
64,
215
],
[
215,
... | [
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
... | Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Grepaf... |
DB00295 | DB00598 | 475 | 1,523 | [
"DDInter1244",
"DDInter1013"
] | Morphine | Labetalol | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Moderate | 1 | [
[
[
475,
24,
1523
]
],
[
[
475,
24,
211
],
[
211,
1,
1523
]
],
[
[
475,
6,
12523
],
[
12523,
45,
1523
]
],
[
[
475,
21,
28827
],
[
28827,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Labetalol (Compound)
Morphine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Labetalol (Compound)
Morphine (Compound) causes Orthostatic hypotension (Side Effect) and O... |
DB00087 | DB14783 | 599 | 287 | [
"DDInter41",
"DDInter574"
] | Alemtuzumab | Diroximel fumarate | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
599,
24,
287
]
],
[
[
599,
24,
1101
],
[
1101,
24,
287
]
],
[
[
599,
63,
541
],
[
541,
24,
287
]
],
[
[
599,
25,
1510
],
[
1510,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Muromonab a... |
DB01110 | DB01126 | 86 | 1,260 | [
"DDInter1209",
"DDInter611"
] | Miconazole | Dutasteride | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestos... | Moderate | 1 | [
[
[
86,
24,
1260
]
],
[
[
86,
6,
8374
],
[
8374,
45,
1260
]
],
[
[
86,
21,
28734
],
[
28734,
60,
1260
]
],
[
[
86,
24,
129
],
[
129,
... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dutasteride"
]
],
[
[
"Miconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Miconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dutasteride (Compound)
Miconazole (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Dutasteride (Compound)
Miconazole may cause a moderate interaction that could exacerbate diseases when ta... |
DB11652 | DB11979 | 1,155 | 1,320 | [
"DDInter1891",
"DDInter625"
] | Tucatinib | Elagolix | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1155,
24,
1320
]
],
[
[
1155,
63,
168
],
[
168,
23,
1320
]
],
[
[
1155,
25,
1297
],
[
1297,
24,
1320
]
],
[
[
1155,
63,
79
],
[
79,
... | [
[
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Tucatinib may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause a ... |
DB00712 | DB04865 | 1,274 | 4 | [
"DDInter763",
"DDInter1335"
] | Flurbiprofen | Omacetaxine mepesuccinate | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
1274,
25,
4
]
],
[
[
1274,
18,
7623
],
[
7623,
46,
4
]
],
[
[
1274,
7,
3218
],
[
3218,
46,
4
]
],
[
[
1274,
6,
7720
],
[
7720,
4... | [
[
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) downregulates {v} (Gene)",
"RRP12"
],
[
"RRP12",
"{u} (Gene) is upregulated by ... | Flurbiprofen (Compound) downregulates RRP12 (Gene) and RRP12 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Flurbiprofen (Compound) upregulates IKBKE (Gene) and IKBKE (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Flurbiprofen (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated b... |
DB00081 | DB01240 | 273 | 885 | [
"DDInter1838",
"DDInter657"
] | Tositumomab | Epoprostenol | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Major | 2 | [
[
[
273,
25,
885
]
],
[
[
273,
25,
1061
],
[
1061,
1,
885
]
],
[
[
273,
23,
539
],
[
539,
62,
885
]
],
[
[
273,
25,
1512
],
[
1512,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
... | Tositumomab may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Tositumomab may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical ef... |
DB00196 | DB12010 | 600 | 214 | [
"DDInter743",
"DDInter785"
] | Fluconazole | Fostamatinib | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
600,
24,
214
]
],
[
[
600,
25,
976
],
[
976,
24,
214
]
],
[
[
600,
24,
1428
],
[
1428,
24,
214
]
],
[
[
600,
24,
861
],
[
861,
6... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofac... | Fluconazole may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may ... |
DB00475 | DB00486 | 1,119 | 1,614 | [
"DDInter355",
"DDInter1253"
] | Chlordiazepoxide | Nabilone | An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
1119,
24,
1614
]
],
[
[
1119,
63,
530
],
[
530,
1,
1614
]
],
[
[
1119,
63,
999
],
[
999,
24,
1614
]
],
[
[
1119,
1,
686
],
[
686,
... | [
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]... | Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate ... |
DB00543 | DB11978 | 87 | 124 | [
"DDInter82",
"DDInter822"
] | Amoxapine | Glasdegib | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
87,
24,
124
]
],
[
[
87,
23,
112
],
[
112,
23,
124
]
],
[
[
87,
63,
475
],
[
475,
24,
124
]
],
[
[
87,
24,
688
],
[
688,
24,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Amoxapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine ... |
DB09039 | DB09065 | 1,670 | 760 | [
"DDInter629",
"DDInter424"
] | Eliglustat | Cobicistat | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
1670,
25,
760
]
],
[
[
1670,
62,
479
],
[
479,
23,
760
]
],
[
[
1670,
64,
271
],
[
271,
23,
760
]
],
[
[
1670,
63,
1204
],
[
1204,
... | [
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Eliglustat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
... | Eliglustat may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Eliglustat may lead to a major life threatening interaction when taken with Mirabegron and Mirabegron may cause a mino... |
DB01142 | DB01409 | 1,264 | 1,415 | [
"DDInter593",
"DDInter1815"
] | Doxepin | Tiotropium | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
1264,
24,
1415
]
],
[
[
1264,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
1264,
21,
29313
],
[
29313,
60,
1415
]
],
[
[
1264,
63,
752
],
[
75... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"... | Doxepin (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Doxepin (Compound) causes Herpes zoster (Side Effect) and Herpes zoster (Side Effect) is caused by Tiotropium (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetid... |
DB00241 | DB00539 | 288 | 11 | [
"DDInter257",
"DDInter1837"
] | Butalbital | Toremifene | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Moderate | 1 | [
[
[
288,
24,
11
]
],
[
[
288,
24,
1594
],
[
1594,
40,
11
]
],
[
[
288,
24,
112
],
[
112,
62,
11
]
],
[
[
288,
24,
723
],
[
723,
63,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Toremifene (Compound)
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that ca... |
DB04953 | DB05812 | 495 | 1,374 | [
"DDInter708",
"DDInter8"
] | Ezogabine | Abiraterone | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
495,
24,
1374
]
],
[
[
495,
21,
28695
],
[
28695,
60,
1374
]
],
[
[
495,
62,
112
],
[
112,
23,
1374
]
],
[
[
495,
23,
1135
],
[
1135,
... | [
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Ezogabine",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused ... | Ezogabine (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Abiraterone (Compound)
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Abirater... |
DB00604 | DB00675 | 1,425 | 888 | [
"DDInter385",
"DDInter1744"
] | Cisapride | Tamoxifen | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Major | 2 | [
[
[
1425,
25,
888
]
],
[
[
1425,
25,
675
],
[
675,
25,
888
]
],
[
[
1425,
24,
543
],
[
543,
63,
888
]
],
[
[
1425,
6,
6799
],
[
6799,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",... | Cisapride may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a ... |
DB00976 | DB08871 | 1,056 | 36 | [
"DDInter1758",
"DDInter666"
] | Telithromycin | Eribulin | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1056,
24,
36
]
],
[
[
1056,
24,
973
],
[
973,
24,
36
]
],
[
[
1056,
64,
1424
],
[
1424,
24,
36
]
],
[
[
1056,
63,
1674
],
[
1674,
... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
... | Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Telithromycin may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a ... |
DB00295 | DB01294 | 475 | 266 | [
"DDInter1244",
"DDInter215"
] | Morphine | Bismuth subsalicylate | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Moderate | 1 | [
[
[
475,
24,
266
]
],
[
[
475,
21,
28643
],
[
28643,
60,
266
]
],
[
[
475,
24,
1347
],
[
1347,
24,
266
]
],
[
[
475,
24,
578
],
[
578,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) ... | Morphine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Bismuth subsalicylate (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00836 | DB01155 | 543 | 872 | [
"DDInter1088",
"DDInter813"
] | Loperamide | Gemifloxacin | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Moderate | 1 | [
[
[
543,
24,
872
]
],
[
[
543,
24,
739
],
[
739,
1,
872
]
],
[
[
543,
24,
945
],
[
945,
40,
872
]
],
[
[
543,
63,
1176
],
[
1176,
1,... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin... |
DB00205 | DB00995 | 929 | 1,112 | [
"DDInter1550",
"DDInter139"
] | Pyrimethamine | Auranofin | One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme ox... | Major | 2 | [
[
[
929,
25,
1112
]
],
[
[
929,
7,
2067
],
[
2067,
45,
1112
]
],
[
[
929,
7,
7720
],
[
7720,
46,
1112
]
],
[
[
929,
18,
1917
],
[
1917,
... | [
[
[
"Pyrimethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Auranofin"
]
],
[
[
"Pyrimethamine",
"{u} (Compound) upregulates {v} (Gene)",
"IKBKB"
],
[
"IKBKB",
"{u} (Gene) is bound by {v} (Compound)",
... | Pyrimethamine (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Auranofin (Compound)
Pyrimethamine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Auranofin (Compound)
Pyrimethamine (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Auranofin (Compound)
Py... |
DB01610 | DB06810 | 248 | 397 | [
"DDInter1912",
"DDInter1484"
] | Valganciclovir | Plicamycin | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Moderate | 1 | [
[
[
248,
24,
397
]
],
[
[
248,
63,
597
],
[
597,
24,
397
]
],
[
[
248,
24,
384
],
[
384,
63,
397
]
],
[
[
248,
40,
563
],
[
563,
24,... | [
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
]
],
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
... | Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Ide... |
DB09389 | DB14723 | 517 | 159 | [
"DDInter1315",
"DDInter1026"
] | Norgestrel | Larotrectinib | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
517,
24,
159
]
],
[
[
517,
24,
1619
],
[
1619,
24,
159
]
],
[
[
517,
63,
392
],
[
392,
24,
159
]
],
[
[
517,
62,
1130
],
[
1130,
... | [
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapati... |
DB00227 | DB12500 | 1,463 | 283 | [
"DDInter1098",
"DDInter714"
] | Lovastatin | Fedratinib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1463,
24,
283
]
],
[
[
1463,
24,
466
],
[
466,
62,
283
]
],
[
[
1463,
24,
351
],
[
351,
23,
283
]
],
[
[
1463,
24,
1419
],
[
1419,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribo... |
DB00531 | DB00916 | 450 | 112 | [
"DDInter456",
"DDInter1202"
] | Cyclophosphamide | Metronidazole | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
450,
24,
112
]
],
[
[
450,
6,
3486
],
[
3486,
45,
112
]
],
[
[
450,
21,
29028
],
[
29028,
60,
112
]
],
[
[
450,
24,
51
],
[
51,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {... | Cyclophosphamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound)
Cyclophosphamide (Compound) causes Encephalopathy (Side Effect) and Encephalopathy (Side Effect) is caused by Metronidazole (Compound)
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases w... |
DB00626 | DB00877 | 1,441 | 629 | [
"DDInter161",
"DDInter1678"
] | Bacitracin | Sirolimus | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
1441,
25,
629
]
],
[
[
1441,
7,
3492
],
[
3492,
46,
629
]
],
[
[
1441,
18,
4360
],
[
4360,
57,
629
]
],
[
[
1441,
21,
28719
],
[
28719... | [
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Bacitracin",
"{u} (Compound) upregulates {v} (Gene)",
"E2F2"
],
[
"E2F2",
"{u} (Gene) is upregulated by {v} (Compound)",
"... | Bacitracin (Compound) upregulates E2F2 (Gene) and E2F2 (Gene) is upregulated by Sirolimus (Compound)
Bacitracin (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Sirolimus (Compound)
Bacitracin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Sirolimus (Compound)
Bacitra... |
DB00722 | DB06723 | 743 | 115 | [
"DDInter1079",
"DDInter58"
] | Lisinopril | Aluminum hydroxide | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
743,
23,
115
]
],
[
[
743,
21,
28643
],
[
28643,
60,
115
]
],
[
[
743,
1,
1058
],
[
1058,
23,
115
]
],
[
[
743,
63,
870
],
[
870,
... | [
[
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Lisinopril",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) i... | Lisinopril (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Aluminum hydroxide (Compound)
Lisinopril (Compound) resembles Moexipril (Compound) and Moexipril may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Lisinopril may cause a moderate ... |
DB01203 | DB08895 | 699 | 976 | [
"DDInter1255",
"DDInter1825"
] | Nadolol | Tofacitinib | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
699,
24,
976
]
],
[
[
699,
24,
407
],
[
407,
63,
976
]
],
[
[
699,
63,
475
],
[
475,
24,
976
]
],
[
[
699,
62,
1479
],
[
1479,
2... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium... | Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a mo... |
DB00283 | DB04844 | 701 | 843 | [
"DDInter395",
"DDInter1778"
] | Clemastine | Tetrabenazine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
701,
24,
843
]
],
[
[
701,
24,
479
],
[
479,
40,
843
]
],
[
[
701,
6,
12523
],
[
12523,
45,
843
]
],
[
[
701,
21,
28698
],
[
28698,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Clemastine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Clemastine (Compound) causes Insomnia (Side Effect) and Insomn... |
DB00035 | DB00531 | 1,314 | 450 | [
"DDInter507",
"DDInter456"
] | Desmopressin | Cyclophosphamide | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Moderate | 1 | [
[
[
1314,
24,
450
]
],
[
[
1314,
21,
29544
],
[
29544,
60,
450
]
],
[
[
1314,
24,
831
],
[
831,
23,
450
]
],
[
[
1314,
24,
589
],
[
589,
... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Weight increased"
],
[
"Weight increased",
"{... | Desmopressin (Compound) causes Weight increased (Side Effect) and Weight increased (Side Effect) is caused by Cyclophosphamide (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a minor interaction that can limit clinical effec... |
DB00889 | DB09048 | 1,133 | 555 | [
"DDInter840",
"DDInter1284"
] | Granisetron | Netupitant | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Moderate | 1 | [
[
[
1133,
24,
555
]
],
[
[
1133,
63,
1101
],
[
1101,
23,
555
]
],
[
[
1133,
24,
283
],
[
283,
62,
555
]
],
[
[
1133,
63,
1181
],
[
1181,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedrat... |
DB00065 | DB14783 | 581 | 287 | [
"DDInter923",
"DDInter574"
] | Infliximab | Diroximel fumarate | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Major | 2 | [
[
[
581,
25,
287
]
],
[
[
581,
25,
1101
],
[
1101,
24,
287
]
],
[
[
581,
64,
1560
],
[
1560,
24,
287
]
],
[
[
581,
24,
599
],
[
599,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
... | Infliximab may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Infliximab may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a m... |
DB00556 | DB04868 | 1,262 | 478 | [
"DDInter1429",
"DDInter1293"
] | Perflutren | Nilotinib | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
1262,
25,
478
]
],
[
[
1262,
21,
28762
],
[
28762,
60,
478
]
],
[
[
1262,
23,
112
],
[
112,
23,
478
]
],
[
[
1262,
24,
688
],
[
688,
... | [
[
[
"Perflutren",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Perflutren",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compoun... | Perflutren (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nilotinib (Compound)
Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Nilotini... |
DB00059 | DB00227 | 1,560 | 1,463 | [
"DDInter1404",
"DDInter1098"
] | Pegaspargase | Lovastatin | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Moderate | 1 | [
[
[
1560,
24,
1463
]
],
[
[
1560,
24,
681
],
[
681,
1,
1463
]
],
[
[
1560,
24,
123
],
[
123,
62,
1463
]
],
[
[
1560,
24,
1613
],
[
1613,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pravastatin"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pravastatin and Pravastatin (Compound) resembles Lovastatin (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a minor interaction that can ... |
DB00992 | DB01246 | 842 | 820 | [
"DDInter1182",
"DDInter45"
] | Methyl aminolevulinate (topical) | Alimemazine | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
842,
24,
820
]
],
[
[
842,
63,
104
],
[
104,
40,
820
]
],
[
[
842,
63,
508
],
[
508,
1,
820
]
],
[
[
842,
24,
9
],
[
9,
1,
... | [
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Me... | Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Methyl aminolevulinate may c... |
DB00209 | DB00835 | 352 | 100 | [
"DDInter1886",
"DDInter245"
] | Trospium | Brompheniramine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
352,
24,
100
]
],
[
[
352,
24,
832
],
[
832,
24,
100
]
],
[
[
352,
24,
211
],
[
211,
63,
100
]
],
[
[
352,
6,
12523
],
[
12523,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine ... |
DB00277 | DB06168 | 1,031 | 1,531 | [
"DDInter1791",
"DDInter281"
] | Theophylline | Canakinumab | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1031,
24,
1531
]
],
[
[
1031,
23,
523
],
[
523,
24,
1531
]
],
[
[
1031,
24,
1362
],
[
1362,
63,
1531
]
],
[
[
1031,
24,
617
],
[
617,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alprazolam"
],
[... | Theophylline may cause a minor interaction that can limit clinical effects when taken with Alprazolam and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olapa... |
DB00393 | DB09065 | 854 | 760 | [
"DDInter1295",
"DDInter424"
] | Nimodipine | Cobicistat | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
854,
25,
760
]
],
[
[
854,
63,
1101
],
[
1101,
23,
760
]
],
[
[
854,
24,
723
],
[
723,
24,
760
]
],
[
[
854,
25,
609
],
[
609,
2... | [
[
[
"Nimodipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepita... |
DB06209 | DB09068 | 256 | 1,427 | [
"DDInter1508",
"DDInter1948"
] | Prasugrel | Vortioxetine | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
256,
24,
1427
]
],
[
[
256,
64,
25
],
[
25,
24,
1427
]
],
[
[
256,
63,
477
],
[
477,
24,
1427
]
],
[
[
256,
25,
802
],
[
802,
24... | [
[
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistrep... | Prasugrel may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may ca... |
DB00831 | DB01176 | 1,178 | 537 | [
"DDInter1866",
"DDInter453"
] | Trifluoperazine | Cyclizine | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
1178,
24,
537
]
],
[
[
1178,
24,
1511
],
[
1511,
63,
537
]
],
[
[
1178,
63,
1242
],
[
1242,
24,
537
]
],
[
[
1178,
35,
104
],
[
104,
... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]... | Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine... |
DB00995 | DB05773 | 1,112 | 1,047 | [
"DDInter139",
"DDInter1848"
] | Auranofin | Trastuzumab emtansine | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme ox... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
1112,
24,
1047
]
],
[
[
1112,
24,
375
],
[
375,
63,
1047
]
],
[
[
1112,
63,
458
],
[
458,
24,
1047
]
],
[
[
1112,
24,
1488
],
[
1488,
... | [
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol... | Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Auranofin may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01174 | DB01612 | 697 | 1,637 | [
"DDInter1442",
"DDInter92"
] | Phenobarbital | Amyl Nitrite | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
697,
24,
1637
]
],
[
[
697,
64,
475
],
[
475,
24,
1637
]
],
[
[
697,
63,
1061
],
[
1061,
24,
1637
]
],
[
[
697,
24,
820
],
[
820,
... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morp... | Phenobarbital may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil ma... |
DB08903 | DB11901 | 996 | 913 | [
"DDInter170",
"DDInter107"
] | Bedaquiline | Apalutamide | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
996,
25,
913
]
],
[
[
996,
62,
112
],
[
112,
23,
913
]
],
[
[
996,
64,
600
],
[
600,
24,
913
]
],
[
[
996,
24,
28
],
[
28,
24,
... | [
[
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Bedaquiline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Bedaquiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Bedaquiline may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may... |
DB00434 | DB01409 | 13 | 1,415 | [
"DDInter459",
"DDInter1815"
] | Cyproheptadine | Tiotropium | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
13,
24,
1415
]
],
[
[
13,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
13,
21,
28680
],
[
28680,
60,
1415
]
],
[
[
13,
24,
146
],
[
146,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compo... | Cyproheptadine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Cyproheptadine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Tiotropium (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Pr... |
DB00783 | DB01060 | 1,438 | 319 | [
"DDInter679",
"DDInter83"
] | Estradiol | Amoxicillin | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to [penicillin] and [ampicillin], but leads to higher serum concentrations than ampicillin. Amoxicillin was granted FDA approval on 18 January 1974. | Moderate | 1 | [
[
[
1438,
24,
319
]
],
[
[
1438,
6,
10215
],
[
10215,
45,
319
]
],
[
[
1438,
21,
28703
],
[
28703,
60,
319
]
],
[
[
1438,
24,
609
],
[
609... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxicillin"
]
],
[
[
"Estradiol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)"... | Estradiol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Amoxicillin (Compound)
Estradiol (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Amoxicillin (Compound)
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and C... |
DB00341 | DB01227 | 1,242 | 1,301 | [
"DDInter343",
"DDInter1043"
] | Cetirizine | Levacetylmethadol | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Moderate | 1 | [
[
[
1242,
24,
1301
]
],
[
[
1242,
24,
649
],
[
649,
1,
1301
]
],
[
[
1242,
63,
576
],
[
576,
1,
1301
]
],
[
[
1242,
40,
11314
],
[
11314,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Levacetylmethadol (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone (Compound) resembles Levacetylmethadol... |
DB00384 | DB09135 | 1,275 | 1,211 | [
"DDInter1859",
"DDInter967"
] | Triamterene | Ioxilan | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Moderate | 1 | [
[
[
1275,
24,
1211
]
],
[
[
1275,
63,
1648
],
[
1648,
24,
1211
]
],
[
[
1275,
24,
1512
],
[
1512,
25,
1211
]
],
[
[
1275,
63,
1645
],
[
16... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclo... |
DB00197 | DB00279 | 1,324 | 1,152 | [
"DDInter1881",
"DDInter1074"
] | Troglitazone | Liothyronine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Moderate | 1 | [
[
[
1324,
24,
1152
]
],
[
[
1324,
24,
624
],
[
624,
40,
1152
]
],
[
[
1324,
24,
467
],
[
467,
62,
1152
]
],
[
[
1324,
24,
1463
],
[
1463,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
],
[... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Liotrix and Liotrix (Compound) resembles Liothyronine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can li... |
DB00357 | DB00471 | 1,051 | 201 | [
"DDInter71",
"DDInter1242"
] | Aminoglutethimide | Montelukast | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Moderate | 1 | [
[
[
1051,
24,
201
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
201
]
],
[
[
1051,
21,
28787
],
[
28787,
60,
201
]
],
[
[
1051,
24,
1220
],
[
1220... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Montelukast"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {... | Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Montelukast (Compound)
Aminoglutethimide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Montelukast (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken... |
DB01210 | DB08884 | 668 | 796 | [
"DDInter1050",
"DDInter800"
] | Levobunolol (ophthalmic) | Gadoxetic acid | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrener... | Gadoxetic acid (gadoxetate) is a paramagnetic gadolinium-containing ionic linear contrast agent in which its salt form, gadoxetate disodium, is used for intravenous injection. Ethoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up ... | Moderate | 1 | [
[
[
668,
24,
796
]
],
[
[
668,
63,
457
],
[
457,
1,
796
]
],
[
[
668,
24,
1106
],
[
1106,
1,
796
]
],
[
[
668,
21,
28841
],
[
28841,
... | [
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoxetic acid"
]
],
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
],
... | Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoxetic acid
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadoxetic acid (Compound)
Levobunolol may cause a moderate interaction t... |
DB00911 | DB11901 | 458 | 913 | [
"DDInter1811",
"DDInter107"
] | Tinidazole | Apalutamide | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
458,
24,
913
]
],
[
[
458,
40,
112
],
[
112,
23,
913
]
],
[
[
458,
24,
110
],
[
110,
62,
913
]
],
[
[
458,
24,
279
],
[
279,
24,... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Tinidazole",
"{u} (Compound) resembles {v} (Compound)",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a ... | Tinidazole (Compound) resembles Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a minor in... |
DB05679 | DB11003 | 1,683 | 748 | [
"DDInter1907",
"DDInter100"
] | Ustekinumab | Anthrax vaccine | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1683,
24,
748
]
],
[
[
1683,
63,
322
],
[
322,
24,
748
]
],
[
[
1683,
24,
594
],
[
594,
24,
748
]
],
[
[
1683,
24,
564
],
[
564,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and ... |
DB00376 | DB01142 | 1,105 | 1,264 | [
"DDInter1870",
"DDInter593"
] | Trihexyphenidyl | Doxepin | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1105,
24,
1264
]
],
[
[
1105,
24,
401
],
[
401,
24,
1264
]
],
[
[
1105,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
1105,
24,
649
],
[
649,
... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],... | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine... |
DB00620 | DB00872 | 175 | 1,080 | [
"DDInter1855",
"DDInter438"
] | Triamcinolone | Conivaptan | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Major | 2 | [
[
[
175,
25,
1080
]
],
[
[
175,
6,
8374
],
[
8374,
45,
1080
]
],
[
[
175,
21,
28769
],
[
28769,
60,
1080
]
],
[
[
175,
24,
126
],
[
126,
... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"C... | Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Conivaptan (Compound)
Triamcinolone (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Conivaptan (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01197 | DB11921 | 1,603 | 1,019 | [
"DDInter292",
"DDInter492"
] | Captopril | Deflazacort | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1603,
24,
1019
]
],
[
[
1603,
63,
959
],
[
959,
24,
1019
]
],
[
[
1603,
24,
761
],
[
761,
24,
1019
]
],
[
[
1603,
23,
286
],
[
286,
... | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Captopril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxaglip... |
DB01396 | DB06792 | 1,482 | 1,606 | [
"DDInter553",
"DDInter1023"
] | Digitoxin | Lanthanum carbonate | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led... | Moderate | 1 | [
[
[
1482,
24,
1606
]
],
[
[
1482,
63,
1152
],
[
1152,
24,
1606
]
],
[
[
1482,
40,
1252
],
[
1252,
24,
1606
]
],
[
[
1482,
63,
1152
],
[
11... | [
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],... | Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Digitoxin (Compound) resembles Digoxin (Compound) and Digoxin may cause a moderate interaction that ... |
DB00678 | DB08899 | 240 | 129 | [
"DDInter1095",
"DDInter649"
] | Losartan | Enzalutamide | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
240,
24,
129
]
],
[
[
240,
6,
8374
],
[
8374,
45,
129
]
],
[
[
240,
21,
29377
],
[
29377,
60,
129
]
],
[
[
240,
63,
1512
],
[
1512,
... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Losartan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Losartan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Losartan (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Enzalutamide (Compound)
Losartan may cause a moderate interaction that could exacerbate diseases when taken with... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.